Intraocular pressure rise is predictive of vision improvement after intravitreal triamcinolone acetonide for diabetic macular oedema: a retrospective analysis of data from a randomised controlled trial

Table 1 Baseline characteristics of 33 eyes treated with IVTA stratified with respect of change in IOP from baseline

Characteristic	IOP change < 5 mmHg rise	IOP rise 5–9 mmHg	IOP rise ≥ 10 mmHg	P value
Characteristic	(n = 17)	(n = 8)	(n = 8)	P value
Age (y)	63.8 ± 8.4	63.9 ± 15.7	61.5 ± 7.2	0.864
Gender, female (n)	9 (53%)	4 (50%)	2 (25%)	0.440
HbA1c ^a	7.9 ± 1.2	9.1 ± 1.5	8.2 ± 1.5	0.295
Phakia, pseudophakic (n)	3 (18%)	2 (25%)	1 (14%)	0.862
IOP (mmHg)	16.9 ± 2.4	15.8 ± 3.1	16.6 ± 2.6	0.600
BCVA (letters)	60.1 ± 14.0	62.9 ± 6.7	58.5 ± 12.7	0.771
CMT (μm) ^b	436 ± 146	443 ± 132	468 ± 22	0.916

IVTA = intravitreal triamcinolone; IOP = intraocular pressure; BCVA = best-corrected visual acuity; CMT = central macular thickness.
Values are mean ± standard deviation or median with interquartile range shown in box brackets.
^an = 13, 4 and 7 for IOP rise <5 mmHg, 5-9 mmHg and ≥10 mmHg, respectively.
^bn = 12, 5 and 4 for IOP rise <5 mmHg, 5-9 mmHg and ≥10 mmHg, respectively.

ISSN: 1471-2415